|
AASLD
Liver Meeting Starts Today in Boston
 |
 |
 |
 |
 |
 |
 |
| SUMMARY:
The
60th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD) --
better known as "The
Liver Meeting" -- gets underway Friday,
October 30, and will run through November
1 at the Hynes Convention Center in Boston.
Treatments for hepatitis B and C will feature
prominently in the conference program. |
|
 |
 |
 |
 |
 |
 |
 |
The
Liver Meeting covers all aspects of liver disease, but
a significant proportion of the nearly 2000 abstracts
to be presented are devoted to treatment and management
of patients with viral hepatitis.
Approximately
10% of Americans have some form of liver disease, according
to the conference organizers. Liver cancer is one of
the few cancers growing in incidence, and the ongoing
obesity epidemic "has dire consequences for the
nation's liver health and wellness."
Several
pharmaceutical companies have already announced some
of the new data to be presented on their experimental
therapies:
Bristol-Myers
Squibb: data on 4 compounds including approved anti-HBV
drug entecavir
(Baraclude), experimental HCV protease inhibitor
BMS-650032, pegylated interferon lambda, and investigational
compound brivanib for treatment of hepatocellular carcinoma.
GlobeImmune: late-breaker presentation on GI-5005
therapeutic HCV vaccine.
Idera Pharmaceuticals: data on DNA-based toll-like
receptor 9 (TLR9) agonist IM0-2125
for HCV treatment.
Roche: data from a study of the experimental
HCV protease inhibitor RG7227
(ITMN-191) plus an HCV polymerase inhibitor.
Schering-Plough: data on investigational HCV
protease inhibitor boceprevir
(including SPRINT-1 results) and next-generation HCV
protease inhibitor narlaprevir (SCH 900518), as well
as studies of pegylated
interferon alfa-2b (PegIntron).
Scynexis:
Phase 1b data on novel anti-HCV agent SCY-635.
Vertex: sustained virological response (SVR)
data Study C208 and final PROVE-3 results on investigational
HCV protease inhibitor telaprevir.
For
further information about the Liver Meeting program,
see www.aasld.org/thelivermeeting.
10/30/09
Sources
American
Association for the Study of Liver Diseases.
Bristol-Myers
Squibb. New Data on Four Bristol-Myers Squibb Compounds
to Be Presented at AASLD 2009. Press release. October
1, 2009.
Bristol-Myers
Squibb and ZymoGenetics. Bristol-Myers Squibb and ZymoGenetics
to Present Final Phase Ib Data on PEG-Interferon Lambda
at AASLD 2009. Press release. October 1, 2009.
GlobeImmune.
GlobeImmune Announces Late-Breaker Presentation of GI-5005
Treatment Response Data at AASLD 2009 Meeting. Press
release. October 6, 2009.
Schering-Plough
. Schering-Plough Highlights Boceprevir, Narlaprevir
(SCH 900518) and PegIntron Data at the American Association
for the Study of Liver Diseases (AASLD) 2009 Annual
Meeting. Press release. October 15, 2009.
Vertex. Vertex Pharmaceuticals Announces Publication
of Telaprevir Abstracts for Presentation at the 60th
AASLD Meeting. Press release. September 24, 2009.
|
